195 related articles for article (PubMed ID: 17954483)
1. Update on clinical gene therapy in childhood.
Qasim W; Gaspar HB; Thrasher AJ
Arch Dis Child; 2007 Nov; 92(11):1028-31. PubMed ID: 17954483
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for adenosine deaminase deficiency.
Cappelli B; Aiuti A
Immunol Allergy Clin North Am; 2010 May; 30(2):249-60. PubMed ID: 20493400
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
[TBL] [Abstract][Full Text] [Related]
4. Genetic manipulation of hematopoietic stem cells in adenosine deaminase deficiency.
Williams DA; Moritz T
Adv Exp Med Biol; 1994; 370():395-400. PubMed ID: 7660937
[No Abstract] [Full Text] [Related]
5. Gene therapy for ADA-SCID, the first marketing approval of an
Aiuti A; Roncarolo MG; Naldini L
EMBO Mol Med; 2017 Jun; 9(6):737-740. PubMed ID: 28396566
[TBL] [Abstract][Full Text] [Related]
6. Gene transfer into hematopoietic stem cells: prospects for human gene therapy.
Einerhand MP; Valerio D
Curr Top Microbiol Immunol; 1992; 177():217-35. PubMed ID: 1353431
[No Abstract] [Full Text] [Related]
7. Gene therapy for severe combined immunodeficiencies.
Gaspar HB; Thrasher AJ
Expert Opin Biol Ther; 2005 Sep; 5(9):1175-82. PubMed ID: 16120048
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.
Candotti F; Shaw KL; Muul L; Carbonaro D; Sokolic R; Choi C; Schurman SH; Garabedian E; Kesserwan C; Jagadeesh GJ; Fu PY; Gschweng E; Cooper A; Tisdale JF; Weinberg KI; Crooks GM; Kapoor N; Shah A; Abdel-Azim H; Yu XJ; Smogorzewska M; Wayne AS; Rosenblatt HM; Davis CM; Hanson C; Rishi RG; Wang X; Gjertson D; Yang OO; Balamurugan A; Bauer G; Ireland JA; Engel BC; Podsakoff GM; Hershfield MS; Blaese RM; Parkman R; Kohn DB
Blood; 2012 Nov; 120(18):3635-46. PubMed ID: 22968453
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.
Shaw KL; Garabedian E; Mishra S; Barman P; Davila A; Carbonaro D; Shupien S; Silvin C; Geiger S; Nowicki B; Smogorzewska EM; Brown B; Wang X; de Oliveira S; Choi Y; Ikeda A; Terrazas D; Fu PY; Yu A; Fernandez BC; Cooper AR; Engel B; Podsakoff G; Balamurugan A; Anderson S; Muul L; Jagadeesh GJ; Kapoor N; Tse J; Moore TB; Purdy K; Rishi R; Mohan K; Skoda-Smith S; Buchbinder D; Abraham RS; Scharenberg A; Yang OO; Cornetta K; Gjertson D; Hershfield M; Sokolic R; Candotti F; Kohn DB
J Clin Invest; 2017 May; 127(5):1689-1699. PubMed ID: 28346229
[TBL] [Abstract][Full Text] [Related]
10. The third conference on hematopoietic stem cell gene therapy: biology and technology.
Emery DW; Bodine DM
Mol Ther; 2002 Jun; 5(6):658-63. PubMed ID: 12027548
[No Abstract] [Full Text] [Related]
11. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.
Aiuti A; Slavin S; Aker M; Ficara F; Deola S; Mortellaro A; Morecki S; Andolfi G; Tabucchi A; Carlucci F; Marinello E; Cattaneo F; Vai S; Servida P; Miniero R; Roncarolo MG; Bordignon C
Science; 2002 Jun; 296(5577):2410-3. PubMed ID: 12089448
[TBL] [Abstract][Full Text] [Related]
12. [Gene therapy using retroviral vectors].
Hanawa H; Shimada T
Uirusu; 2003 Dec; 53(2):177-83. PubMed ID: 15071956
[No Abstract] [Full Text] [Related]
13. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Aiuti A; Cattaneo F; Galimberti S; Benninghoff U; Cassani B; Callegaro L; Scaramuzza S; Andolfi G; Mirolo M; Brigida I; Tabucchi A; Carlucci F; Eibl M; Aker M; Slavin S; Al-Mousa H; Al Ghonaium A; Ferster A; Duppenthaler A; Notarangelo L; Wintergerst U; Buckley RH; Bregni M; Marktel S; Valsecchi MG; Rossi P; Ciceri F; Miniero R; Bordignon C; Roncarolo MG
N Engl J Med; 2009 Jan; 360(5):447-58. PubMed ID: 19179314
[TBL] [Abstract][Full Text] [Related]
15. Strategies for retrovirus-based correction of severe, combined immunodeficiency (SCID).
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
Methods Enzymol; 2012; 507():15-27. PubMed ID: 22365767
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID.
Aiuti A; Brigida I; Ferrua F; Cappelli B; Chiesa R; Marktel S; Roncarolo MG
Immunol Res; 2009; 44(1-3):150-9. PubMed ID: 19224139
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for adenosine-deaminase-deficient severe combined immunodeficiency.
Aiuti A
Best Pract Res Clin Haematol; 2004 Sep; 17(3):505-16. PubMed ID: 15498720
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy of primary T cell immunodeficiencies.
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
Gene; 2013 Aug; 525(2):170-3. PubMed ID: 23583799
[TBL] [Abstract][Full Text] [Related]
19. Investor Outlook: Rising from the Ashes; GSK's European Approval of Strimvelis for ADA-SCID.
Schimmer J; Breazzano S
Hum Gene Ther Clin Dev; 2016 Jun; 27(2):57-61. PubMed ID: 27267267
[TBL] [Abstract][Full Text] [Related]
20. ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization.
Ylä-Herttuala S
Mol Ther; 2016 Jun; 24(6):1013-1014. PubMed ID: 27324442
[No Abstract] [Full Text] [Related]
[Next] [New Search]
